Description: Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company's lead drug candidate includes Selinexor, an oral selective inhibitors of nuclear export (SINE) compound that specifically blocks XPO1 cargo binding is in Phase I clinical trials in patients with heavily pretreated relapsed and/or refractory hematological and solid tumor malignancies. Its other drug candidates comprise KPT-350 and related SINE compounds; PAK4 inhibitors; and Verdinexor, a SINE compound that is in Phase IIb clinical trials in pet dogs with newly-diagnosed or first relapse after chemotherapy lymphomas. The company was founded in 2008 and is based in Natick, Massachusetts.
Home Page: www.karyopharm.com
KPTI Technical Analysis
85 Wells Avenue
Newton,
MA
02459
United States
Phone:
617 658 0600
Officers
| Name | Title |
|---|---|
| Mr. Richard A. Paulson M.B.A. | Pres, CEO & Director |
| Dr. Sharon Shacham M.B.A., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board |
| Mr. Michael P. Mason CPA, M.B.A. | Exec. VP, CFO & Treasurer |
| Mr. Ran Frenkel R.Ph., RPh | Global Head of Clinical Operations |
| Dr. Mansoor Raza Mirza M.D. | Clinical Consultant, Member of Scientific Advisory Board & Independent Director |
| Mr. Cameron Peters | VP of Fin., Assistant Treasurer & Principal Accounting Officer |
| Mr. Pierre S. Sayad M.S., Ph.D. | VP of Global Medical & Scientific Affairs |
| Ms. Elhan Webb C.F.A. | Sr. VP of Investor Relations |
| Mr. Michael J. Mano J.D. | Sr. VP, Gen. Counsel & Sec. |
| Mr. James Accumanno J.D. | Chief Compliance Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 12.0484 |
| Price-to-Sales TTM: | 1.0495 |
| IPO Date: | 2013-11-06 |
| Fiscal Year End: | December |
| Full Time Employees: | 442 |